| Title |
Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability
|
|---|---|
| Published in |
Patient preference and adherence, January 2013
|
| DOI | 10.2147/ppa.s39233 |
| Pubmed ID | |
| Authors |
Mark Anderson |
| Abstract |
Prolonged seizures and status epilepticus are a common acute neurological presentation in pediatric practice. As a result, there is a need for effective and safe medications that can be delivered to convulsing children to effect rapid seizure termination both in hospital and community settings. The challenges of achieving intravenous access, particularly in young children, mandate alternative routes of administration for these drugs. Over the last ten years, midazolam delivered via the buccal mucosa has been demonstrated to be efficacious, safe, and acceptable to children and their caregivers, and a formulation has recently been licensed for use in Europe. The aim of this article is to review the clinical pharmacology with respect to these issues. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 33% |
| Turkey | 1 | 11% |
| Spain | 1 | 11% |
| Mexico | 1 | 11% |
| Unknown | 3 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 44% |
| Science communicators (journalists, bloggers, editors) | 2 | 22% |
| Scientists | 2 | 22% |
| Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Czechia | 1 | 2% |
| Unknown | 46 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 21% |
| Student > Bachelor | 6 | 13% |
| Researcher | 5 | 11% |
| Student > Postgraduate | 5 | 11% |
| Student > Ph. D. Student | 3 | 6% |
| Other | 9 | 19% |
| Unknown | 9 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 45% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
| Nursing and Health Professions | 2 | 4% |
| Agricultural and Biological Sciences | 2 | 4% |
| Neuroscience | 2 | 4% |
| Other | 3 | 6% |
| Unknown | 13 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 May 2021.
All research outputs
#6,572,276
of 25,374,917 outputs
Outputs from Patient preference and adherence
#431
of 1,757 outputs
Outputs of similar age
#64,285
of 289,007 outputs
Outputs of similar age from Patient preference and adherence
#3
of 19 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,757 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.5. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,007 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.